Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
Methods, compositions, and devices for transdermally administering an active agent such as memantine are provided.
1. A transdermal delivery system, comprising: an adhesive matrix comprised of an adhesive polymer, a solubilizer, and a memantine salt, the memantine salt consisting of memantine and a levulinic acid counteranion, wherein the adhesive matrix comprises a memantine/levulinic acid ion-pair/salt, and wherein the levulinic acid counteranion is present in an equimolar or greater than equimolar amount relative to memantine.
2. The transdermal system of claim 1 , wherein the adhesive matrix comprises between about 5-15 w/w % of the solubilizer.
3. The transdermal system of claim 1 , wherein the solubilizer is a polar solvent.
4. The transdermal system of claim 1 , wherein the solubilizer is selected from propylene glycol, ethylene glycol, glycerol, alkyl alcohol, N-methyl-pyrrolidone, formamide, acetamide, polyethylene glycol, and diethylene glycol monoethyl ether.
5. The transdermal system of claim 1 , wherein the adhesive matrix comprises about 45-90 w/w % of the adhesive polymer.
6. The transdermal system of claim 5 , wherein the adhesive polymer is selected from a polyisobutylene, an acrylic adhesive polymer, a polystyrene block copolymer, a butyl rubber, and a silicone rubber.
7. The transdermal system of claim 6 , wherein the acrylic adhesive polymer is selected from a polyacrylic acid, a methacrylic acid, a polyacrylate, and a polymethacrylate.
8. The transdermal system of claim 1 , wherein the adhesive matrix layer comprises about 5-20 w/w % memantine salt.
9. The transdermal system of claim 1 , further comprising a contact adhesive layer in direct or indirect contact with the adhesive matrix, the contact adhesive layer comprising a contact layer adhesive polymer and a contact layer solubilizer, and a contact layer memantine salt soluble in the contact layer solubilizer to at least about 10 mg/mL at 25° C.
10. A method of transdermally administering memantine to a subject in need thereof, comprising: providing a transdermal drug delivery system according to claim 1 .